Episode Summary
The WHO's prequalification of a novel oral polio vaccine type 2 (nOPV2) represents a significant advancement in global poliomyelitis eradication efforts. This newly approved vaccine, manufactured by Biological E. Limited in India, enhances the international vaccine supply and strengthens outbreak response capabilities by addressing circulating vaccine-derived poliovirus type 2 (cVDPV2) in under-immunized populations with improved genetic stability and reduced reversion risk.
Key Topics Discussed
- WHO vaccine prequalification process and international standards for quality, safety, and efficacy verification
- Novel oral polio vaccine type 2 (nOPV2) design and genetic stability improvements compared to earlier formulations
- Circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in under-immunized populations and prevention strategies
- Global vaccine manufacturing partnerships and technology transfer from PT Bio Farma (Indonesia) to Biological E. Limited (India)
- Supply chain resilience and UNICEF procurement for international immunization campaigns
- Progress and remaining challenges in achieving global polio eradication goals
Key Takeaways
- nOPV2 prequalification expands the global vaccine manufacturing base, improving supply resilience and procurement capacity for outbreak response
- Enhanced genetic stability of the novel vaccine reduces the risk of circulating vaccine-derived poliovirus emergence while maintaining effective transmission interruption
- International partnerships and technology transfer mechanisms are critical for strengthening public health infrastructure and vaccine equity in developing regions
- Despite significant progress in polio eradication, ongoing surveillance and access to safer, more effective vaccines remain essential in endemic and at-risk regions
About This Episode
This episode addresses a pivotal development in global poliomyelitis control and vaccine innovation. As polio continues to circulate in certain regions despite decades of eradication efforts, vaccine advancement and expanded manufacturing capacity are fundamental to interrupting transmission. The discussion of nOPV2 prequalification is particularly relevant for public health professionals, immunization program managers, and policymakers engaged in disease surveillance and outbreak response. For the Georgian medical community, this episode contextualizes international vaccine standards and global health partnerships that inform national immunization strategies. The episode accompanies peer-reviewed publications and health policy discussions in the Georgian Medical Journal.
In this episode of the GMJ Podcast — the official podcast of the Georgian Medical Journal, we examine a new development from the World Health Organization (WHO) aimed at strengthening the global fight against poliomyelitis.
The WHO has announced the prequalification of an additional novel oral polio vaccine type 2 (nOPV2), expanding global vaccine supply and supporting international efforts to control outbreaks of poliovirus.
Prequalification confirms that the vaccine meets international standards of quality, safety and efficacy, allowing United Nations agencies such as UNICEF to procure and distribute the vaccine for immunization campaigns worldwide.
The novel oral polio vaccine type 2 was developed to address outbreaks caused by circulating vaccine-derived poliovirus type 2 (cVDPV2), which can occur in under-immunized populations. Compared with earlier oral polio vaccines, the new vaccine is designed to be more genetically stable, reducing the risk of triggering new outbreaks while still effectively interrupting virus transmission.
The newly prequalified vaccine is manufactured by Biological E. Limited in India, following technology transfer from PT Bio Farma in Indonesia, expanding the global manufacturing base and improving supply resilience.
The episode discusses several key global health issues:
• Progress toward global polio eradication
• The challenge of circulating vaccine-derived poliovirus outbreaks
• The importance of vaccine innovation in outbreak response
• Strengthening global vaccine supply chains
• The role of international partnerships in disease eradication
Despite enormous progress in reducing polio worldwide, the virus continues to circulate in some regions. Expanding access to safer and more effective vaccines remains essential for achieving the global goal of polio eradication.
Original WHO source discussed in this episode:
https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine
The GMJ Podcast accompanies peer-reviewed publications and global health policy discussions published in the Georgian Medical Journal.
Journal website:
https://gmj.ge/
#გიორგიფხაკაძე #drpkhakadze #sheniekimi